Top ADC Payload Manufacturers Analysis
.png)
Published: May 2026
An antibody-drug conjugate is a targeted cancer therapy that combines the precision of monoclonal antibodies with the potency of cytotoxic drugs. ADCs are designed to more efficiently and effectively treat cancer by specifically identifying and eliminating cancer cells while sparing healthy cells. ADCs represent an established therapeutic concept with over 15 approved products. Notable examples of ADCs approved in 2025 include Telisotuzumab vedotin (AbbVie, May 2025) and Trastuzumab rezetecan (Jiangsu Hengrui, May 2025), Trastuzumab botidotin (Kelun Biotech, October 2025) and Becotatug vedotin (Lepu Biopharma, October 2025).
Cytotoxin payload is one of the active drug components in an ADC. This component can be any chemical agent capable of either treating or inducing the death of a diseased / transformed cell / pathogenic entity. As such, there are two main categories of cytotoxins, namely DNA, damaging agents and microtubule / tubulin polymerization inhibitors. However, recently, topoisomerase inhibitors have also gained attention from various ADC developers as potential cytotoxic agents to be used as payloads in ADCs. Additionally, protein kinase inhibitors and radioimmunoconjugate are being explored by few developers as drug conjugate in ADCs.
The breakthroughs in the design, potency and stability of cytotoxic warheads have substantially enhanced the therapeutic index of ADCs. Modern payloads exhibit enhanced tumor cell penetration and controlled release characteristics, resulting in improved efficacy and safety profiles. These advancements are fueling the market growth for next-generation ADC cytotoxic payloads and warheads.
Roots Analysis has conducted an exhaustive study on featuring the current market landscape and future opportunity for the companies engaged in developing antibody drug conjugates, over a span of next 10 years.
Top ADC Cytotoxic Payloads and Warheads Manufacturers
- CARBOGEN AMCIS
- Cerbios-Pharma
- Levena Biopharma
- MabPlex
- MilliporeSigma (Merck)
- WuXi STA
The figure below highlights the top ADC payload manufacturers:
Interested in exploring ~70 ADC payload manufacturers, including analysis of top players, along with their recent initiatives?
Discover Below the Details on Top ADC Payload Manufacturers Analysis
Let us dive deep into the details of the leading ADC payload manufacturers. It is essential to note that the selection of top players can differ substantially according to the defined criteria.
1. CARBOGEN AMCIS
Company Overview
CARBOGEN AMCIS focuses on providing high-quality chemical process development and manufacturing of highly potent active pharmaceutical ingredients, including antibody-drug conjugate payloads, supporting all stages of drug development from early research through clinical trials to commercial manufacturing. Moreover, the company’s expertise in ADC payloads involves handling the manufacture of highly potent cytotoxic compounds safely and efficiently, critical for targeted cancer biologic therapies. Further, the firm also offers comprehensive services including process research, scale-up, and supply of APIs alongside drug product development.
Product Portfolio
| Parameter | Details | |
| Type of Payload |
|
|
| Scale of Operation |
|
|
| Therapeutic Area |
|
|
Recent Developments
In October 2025, CARBOGEN AMCIS partnered with Celonic, combining Celonic’s biologics expertise with CARBOGEN AMCIS’s payload and conjugation capabilities, creating a seamless, end-to-end ADC development pathway.
To know more about the recent initiatives of CARBOGEN AMCIS and other ADC payload manufactures, access full report.
2. Cerbios-Pharma
Company Overview
Cerbios-Pharma has over 20 years of experience in handling highly potent active pharmaceutical ingredients in its state-of-the-art cGMP manufacturing facilities. These facilities feature two complete lines specifically designed for cytotoxic linker-payload production, capable of handling batch sizes from grams to kilograms, suitable for both clinical and commercial supply. The recently expanded units employ advanced technologies such as high- and low-pressure chromatography, nanofiltration, lyophilization, and isolator containment, reflecting the cutting-edge standards required for oncology ADC payloads.
Product Portfolio
| Parameter | Details | |
| Type of Payload |
|
|
| Scale of Operation |
|
|
Recent Developments
In April 2025, Healthcare Advanced Synthesis (HAS) acquired Cerbios-Pharma. This strengthens HAS’s ADC payload capabilities through Cerbios-Pharma’s expertise in high-potency active pharmaceutical ingredient (HPAPI) manufacturing.
To know more about the recent initiatives of Cerbios-Pharma and other ADC payload manufactures, access full report.
3. Levena Biopharma
Company Overview
Levena Biopharma is a specialized CRO / CDMO committed to advancing antibody-drug conjugate (ADC) therapeutics. The company offers a comprehensive portfolio of validated ADC payloads, proprietary linkers, and custom conjugation solutions for precise and efficient ADC assembly. Levena supports its clients with custom payload synthesis, advanced analytical testing, and fully integrated services from early ADC discovery through scale-up and cGMP manufacturing. The company leverages its deep expertise and innovative technologies, to develop ADCs to address cancer and other unmet medical needs globally.
Product Portfolio
| Parameter | Details | |
| Type of Payload |
|
|
| Type of Linker |
|
|
| Scale of Operation |
|
|
| Therapeutic Area |
|
|
To know more about the recent initiatives of Levena Biopharma and other ADC payload manufactures, access full report.
3. MabPlex
Company Overview
MabPlex is a global CDMO specializing in biopharmaceuticals, with comprehensive expertise in monoclonal antibodies, recombinant proteins and ADCs. It is worth noting that the company has its proprietary technology platforms and robust capabilities for high-potency payload handling, ADC formulation, and large-scale fill-finish, ranking among the top ADC formulation providers worldwide. Moreover, their team offers technical excellence, supporting partners through all stages, including complex process development and rigorous quality management. Through quality-driven innovation and client-centered flexibility, MabPlex supports rapid advancement of ADC therapeutics to market.
Product Portfolio
| Parameter | Details | |
| Type of Payload |
|
|
| Type of Linker |
|
|
| Scale of Operation |
|
|
Recent Developments
In May 2025, MabPlex participated in the BIO Boston, held in Boston, Massachusetts, US. The event provided a platform to showcase their ADC payload manufacturing expertise and explore partnerships in high-potency conjugation technologies.
To know more about the recent initiatives of MabPlex and other ADC payload manufactures, access full report.
4. MilliporeSigma (Merck)
Company Overview
MilliporeSigma has over 15 years of experience in ADC contract development and manufacturing, the company supports biopharmaceutical clients from early clinical phases to commercial supply, leveraging its expansive global network and deep technical expertise. The company’s innovative payload and linker platforms, such as ChetoSensar and DOLCORE, address solubility and synthesis challenges, enabling faster, more efficient ADC development for developers. In 2024, MilliporeSigma introduced the Mobius ADC Reactor, a scalable single-use solution to further advance manufacturing flexibility and efficiency. These capabilities position the company as a trusted partner in ADC innovation.
Product Portfolio
| Parameter | Details | |
| Type of Payload |
|
|
| Scale of Operation |
|
|
Recent Developments
In June 2025, MilliporeSigma entered into a collaboration with Simtra BioPharma Solutions to provide an integrated, manufacturing service for antibody-drug conjugates. This partnership was focused on simplifying the ADC production process, reducing timelines, and accelerating time to market with coordinated program management and high-quality standards.
To know more about the recent initiatives of MilliporeSigma (Merck) and other ADC payload manufactures, access full report.
5. Wuxi STA
Company Overview
Wuxi STA is a leading CDMO which offers comprehensive services encompassing process development, scale-up, and GMP manufacturing of cytotoxic payloads and linkers for antibody-drug conjugates (ADCs). With its manufacturing facilities and expertise in handling highly potent compounds, Wuxi STA supports seamless integration with biologics development by WuXi Biologics, enabling efficient production of complex ADC intermediates. Their robust capabilities and strict quality standards meet global regulatory requirements, facilitating global clinical and commercial ADC manufacturing. It is worth noting that Wuxi STA is recognized for its strategic partnerships that accelerate innovative ADC therapeutics toward clinical evaluation.
Product Portfolio
| Parameter | Details | |
| Type of Payload |
|
|
| Scale of Operation |
|
|
Recent Developments
In December 2024, Wuxi STA signed a research service agreement with Aadi Bioscience to develop and commercialize three novel preclinical ADCs.
To know more about the recent initiatives of Wuxi STA and other ADC payload manufactures, access full report.
What About Other ADC Cytotoxic Payload and Warhead Companies Around the World?
The above article features the leading ADC cytotoxic payload and warhead companies selected from a pool of around 70 manufacturers that we have compiled. If you're interested, you can download the on this topic by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at .
Sources
- https://us.huatengsci.com/news/show/1719.html
- https://www.drugdiscoverynews.com/celonic-group-and-carbogen-amcis-form-strategic-partnership-for-integrated-adc-development-16715
- https://www.specchemonline.com/HAS-Healthcare-Advanced-Synthesis-acquires-Cerbios-Pharma
- https://mabplexinc.com/join-mabplex-at-bio-boston-2025/
- https://www.pharmtech.com/view/milliporesigma-and-simtra-launch-five-year-agreement-for-drug-substance-drug-manufacturing-services
- https://www.wuxibiologics.com/wuxi-biologics-and-hangzhou-dac-signed-research-service-agreement-with-aadi-bioscience-on-three-novel-adcs/